The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitor Advances Into Clinical Practice
1.50 hr(s) | CME , NCPD , MOC , ABIM
Specialty: Ovarian Cancer
Therapeutic Area(s): Oncology , Gynecology
Release Date: June 16, 2021
Expiration Date: June 16, 2021
Location: Live Webcast
The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhibitors are indicated by the FDA for use in patients with BRCA-deficient tumors, homologous recombination deficient (HRD) tumors, and biomarker wild-type tumors and are being investigated in combination with other systemic agents, including targeted therapies, chemotherapy, and immunotherapy, in an effort to overcome PARP resistance and exploit additive efficacy. Join PeerView and the National Ovarian Cancer Coalition for an educational event that will combine a review of key data on PARP inhibitors with practical expert guidance on integrating these agents into clinical practice. Using PeerView’s unique “Candid Conversations & Clinical Consults” format, this virtual event will provide participants with multiple perspectives, including those from clinicians in academic and community settings, patients, and advocates; opportunities to reflect on how treatment advances will affect patient care; and a venue for having oncology experts answer their questions on using PARP inhibitors in a variety of settings. With case patients drawn from practice serving as the framework for the event, the expert faculty panel will delve into critical concepts, including genetic testing guidelines, clinical trial enrollment, and recognizing and managing adverse events associated with PARP inhibitors, and engage in interactive discussions that will bring clinical decision points to life.